Ascendis Pharma: Platform value reaches a wider investor audience; Maintain Buy

Research evidence excerpt

Ascendis Pharma: Platform value reaches a wider investor audience; Maintain Buy

Accessible version

Ascendis Pharma

Platform value reaches a wider investor

audience; Maintain Buy

Maintain Rating: BUY | PO: 288.00 USD | Price: 260.75 USD

Russell index inclusion could expand shareholder audience 29 June 2026

As of late last week, Ascendis Pharma (ticker: ASND) has been added to the Russell Equity

3000, Russell 2500, Russell 1000 and Russell Midcap indexes. In our view, we think the

Tazeen Ahmad

inclusion could help meaningfully expand shareholder exposure and awareness to a more Research Analyst

generalist audience beyond the historical healthcare specialist focus. Importantly, we BofAS +1 646 855 4236

believe the timing is favorable. ASND is transitioning from a development-stage biotech tazeen.ahmad@bofa.com

to a multi-product commercial company with accelerating revenue growth and growing Daniel Giraldo

profitability. As the investor base broadens, we see potential for the stock to earn a Research Analyst BofAS

valuation that is less dependent on individual catalysts and more reflective of durable daniel.giraldoperez@bofa.com

commercial execution and long-term platform value. We maintain our Buy with $288 PO. Jeremiah Lorentz

Research Analyst

M&A speculation reinforces platform value BofASjeremiah.lorentz@bofa.com

We note investor focus on ASND's strategic value has increased following recent third- Wesley Yon

party media reports discussing potential M&A interest in the company. While no ResearchBofAS Analyst

transaction discussions have been confirmed, we believe it is worth highlighting Novo wesley.yon@bofa.com

Nordisk's existing relationship with ASND. Novo maintains a strategic collaboration with Amy Qian